Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1788-1793

  Cato III, Allen ^a,c   Qian, Jiang ^a   Hsu, Ann ^a   Levy, Benjamin ^b   Leonard, John ^a   Granneman, Richard ^a  

^a ABBOTT LABORATORIES   (United States)

^b Natl Medical Research Corporation   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SAFETY; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS RESISTANCE;

EID: 0031836653     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1788     Document Type: Article

References (32)

1. Blum, M. R., S. H. T. Liao, S. S. Good, and P. De Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 (Suppl. 2A): 189-194.
2. Cato, A., A. Hsu, R. Granneman, J. Leonard, G. Carlson, L. Carothers, and G. Cao. 1995. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole, abstr. 133, p. 211. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Cato, A., J. Qian, L. Carothers, G. Carlson, C. Locke, A. Hsu, R. Granneman, and J. Leonard. 1996. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine. Clin. Pharmacol. Ther. 59:144.
4. Collins, J. M., and J. D. Unadkat. 1989. Clinical pharmacokinetics of zidovudine: an overview of current data. Clin. Pharmacokinet. 17:1-9.
5. Cretton, E. M., L. Placidi, and J. P. Sommadossi. 1993. Conversion of 3′-azido-3′-deoxythymidine (AZT) to its toxic metabolite 3′-amino-3′-deoxythymidine (AMT) is mediated by cytochrome P450 and NADPH-cytochrome C reductase in liver microsomes, abstr. PII-78, p. 189. In Abstracts of the 94th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
6. Cretton, E. M., R. F. Schinazi, H. M. McClure, D. C. Anderson, and J. P. Sommadossi. 1991. Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob. Agents Chemother. 35:801-807.
7. Cretton, E. M., and J. P. Sommadossi. 1991. Modulation of 3′-azido-3′-deoxythymidine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem. Pharmacol. 42:1475-1480.
8. Cretton, E. M., M. Y. Xie, R. J. Bevan, N. M. Goudgaon, R. F. Schinazi, and J. P. Sommadossi. 1991. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol. Pharmacol. 39:258-266.
9. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. G. Aguado, J. G. De Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333: 1528-1533.
10. Eagling, V. A., J. L. Howe, M. J. Barry, and D. J. Back. 1994. The metabolism of zidovudine by human liver microsomes in vitro: formalion of 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 48:267-276.
11. Fischl, M. A., D. D. Richman, D. M. Causey, M. H. Grieco, et al. 1989. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-relaled complex. JAMA 262:2405-2410.
12. Hirsch, M. S., and R. T. D'Aquila. 1993. Therapy for human immunodeficiency virus infection. N. Engl. J. Med. 328:1686-1695.
13. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
14. Howe, J. L., D. J. Back, and J. Colbert. 1992. Extrahepatic metabolism of zidovudine. Br. J. Clin. Pharmacol. 33:190-192.
15. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
16. Klecker, R. W., J. M. Collins, R. Yarchoan, R. Thomas, J. F. Jenkins, S. Broder, and C. E. Myers. 1987. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther. 41:407-412.
17. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
18. Kumar, G. N., B. Grabowski, R. Lee, and J. F. Denissen. 1996. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab. Dispos. 24:615-617.
19. Land, S., G. Treloar, D. McPhee, C. Birch, R. Doherty, D. Cooper, and I. Gust. 1990. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J. Infect. Dis. 161:326-329.
20. Langtry, H. D., and D. M. Campoli-Richards. 1989. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37:408-450.
21. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
22. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
23. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J. Chromatogr. B 704:307-313.
24. Maurice, M., L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel. 1992. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6:752-758.
25. Ouellet, D., A. Hsu, J. Qian, J. Cavanaugh, and J. Leonard. 1996. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers, abstr. Mo.B.1198, p. 88. In Abstracts of the XI International Conference on AIDS.
26. Placidi, L., E. M. Cretton, M. Placidi, and J. P. Sommadossi. 1993. Reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P450. Clin. Pharmacol. Ther. 54:168-176.
27. Ragni, M. V., L. A. Kingsley, and S. J. Zhou. 1992. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs. J. Acquired Immune Defic. Syndr. 5:120-126.
28. Richman, D. D. 1990. Zidovudine resistance of human immunodeficiency virus. Rev. Infect. Dis. 12(Suppl. 5):S507-S510.
29. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaughnessy, K. Gelmon, C. Tsoukas, J. Gill, J. Ruedy, and M. A. Wainberg. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3:411-415.
30. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
31. Stagg, M. P., E. M. Cretton, L. Kidd, R. B. Diasio, and J. P. Sommadossi. 1992. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 51:668-676.
32. Zhou, X. J., and J. P. Sommadossi. 1994. Quantification of 3′-amino-3′-deoxythymidine, a toxic catabolite of 3′-azido-3′-deoxythymidine (zidovudine) in human plasma by high-performance liquid chromatography using precolumn derivatization with fluorescamine and fluorescence detection. J. Chromatogr. 656:389-396.